Proteogenix

Revision as of 14:31, 9 August 2011 by Lakshmi Gopalakrishnan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Proteogenix

Articles

Most recent articles on Proteogenix

Most cited articles on Proteogenix

Review articles on Proteogenix

Articles on Proteogenix in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Proteogenix

Images of Proteogenix

Photos of Proteogenix

Podcasts & MP3s on Proteogenix

Videos on Proteogenix

Evidence Based Medicine

Cochrane Collaboration on Proteogenix

Bandolier on Proteogenix

TRIP on Proteogenix

Clinical Trials

Ongoing Trials on Proteogenix at Clinical Trials.gov

Trial results on Proteogenix

Clinical Trials on Proteogenix at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Proteogenix

NICE Guidance on Proteogenix

NHS PRODIGY Guidance

FDA on Proteogenix

CDC on Proteogenix

Books

Books on Proteogenix

News

Proteogenix in the news

Be alerted to news on Proteogenix

News trends on Proteogenix

Commentary

Blogs on Proteogenix

Definitions

Definitions of Proteogenix

Patient Resources / Community

Patient resources on Proteogenix

Discussion groups on Proteogenix

Patient Handouts on Proteogenix

Directions to Hospitals Treating Proteogenix

Risk calculators and risk factors for Proteogenix

Healthcare Provider Resources

Symptoms of Proteogenix

Causes & Risk Factors for Proteogenix

Diagnostic studies for Proteogenix

Treatment of Proteogenix

Continuing Medical Education (CME)

CME Programs on Proteogenix

International

Proteogenix en Espanol

Proteogenix en Francais

Business

Proteogenix in the Marketplace

Patents on Proteogenix

Experimental / Informatics

List of terms related to Proteogenix

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Proteogenix is a corporation based in Portland, Oregon, United States, that develops and markets biomarker diagnostic tests for the detection of life-threatening pregnancy-related conditions. Proteogenix is currently developing non-invasive protein biomarker screening tests for intra-amniotic infection, premature birth, and Down syndrome, which combined cause 175,000 premature births each year in the United States alone.[1]

References

  1. "ProteoGenix News from The BioSpace Beat". Biospace.com. September 29, 2004.


Template:SIB Template:WH Template:WS